AITRICS Tops 100 Hospitals for Vital Care Solution Adoption

AITRICS' patient deterioration prediction solution 'AITRICS-VC (VitalCare)', at the forefront of medical artificial intelligence (AI) innovation, is changing the paradigm of the domestic medical field. Now, over 100 medical institutions have adopted this AI solution, proving its value in real medical settings and expanding its influence. VitalCare goes beyond simple prediction, playing a crucial role in securing the 'golden time' to protect patients' lives. It provides early warnings for acute severe events (death, transfer to ICU, cardiac arrest) that can occur within 6 hours in general wards, and the possibility of sepsis onset within 4 hours. Furthermore, in intensive care units, it predicts the risk of death within 6 hours, helping medical staff respond preemptively. In March 2023, VitalCare made its debut in the non-covered market and has grown at a remarkable pace. As of April 2025, it is actively used in 100 hospitals and approximately 45,000 beds across South Korea, supporting medical staff's rapid and accurate clinical decision-making. In particular, with the accelerated adoption by major medical institutions, including tertiary general hospitals, the cumulative number of beds is rapidly increasing. The fact that additional adoption procedures are currently underway in about 20 hospitals demonstrates how strongly VitalCare's utility is recognized in the medical field. VitalCare's success is leading to AITRICS' robust growth momentum. Its reasonable billing model, which charges daily per bed in proportion to actual usage, has established the solution as AITRICS' main revenue driver within two years of its launch. Throughout 2024, VitalCare recorded annual sales of approximately 10 billion won, securing the company's financial stability. Based on this solid revenue structure, AITRICS is confident in achieving its break-even point (BEP) in the second half of 2025. While further strengthening VitalCare's domestic market leadership, AITRICS is also preparing for a leap into the global market. This year, the company plans to expand its portfolio beyond increasing the number of domestic beds to various medical settings such as emergency rooms, while also accelerating its overseas expansion. Having already obtained US FDA 510(k) clearance last year, AITRICS has established a foothold for entering the US market. The company is currently preparing clinical research with local medical institutions, ready to open a new chapter in the global medical AI market. Kim Kwang-jun, CEO of AITRICS, emphasized, "VitalCare continuously provides tangible value to both medical staff and patients, which is translating into meaningful sales performance." He asserted that by further solidifying institutional trust based on the rich clinical evidence accumulated in the non-covered market and outstanding performance in real medical settings, VitalCare will play a crucial role in future healthcare.